These values were found to be in the expression range of the most frequently encountered genetic aberrations described in peripheral blood or medullary blasts of AML-affected patients at diagnosis (NPM1 mutations, ranging from 10 to 10,000% NPM1/ABL1 or the RUNX1/RUNX1T1 fusion gene, ranging from 100 to 1,000% RUNX1/RUNX1T1/ABL1) [26, 31, 32]. This evidence concerns the gene ABL1 and acute myeloid leukemia.